A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

Martin J. van den Bent,Analia Azaro,Filip de Vos,Juan Manuel Sepúlveda,W. K. Alfred Yung,Patrick Y. Wen,Andrew B. Lassman,Markus Joerger,Ghazaleh Tabatabai,Jordi Rodon,Ralph Tiedt,Sylvia Zhao,Tiina Kirsilae,Yi Cheng,Sergio Vicente,O. Alejandro Balbin,Hefei Zhang,Wolfgang Wick

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

2019

Martin J. van den Bent
Analia Azaro
Filip de Vos
Juan Manuel Sepúlveda
W. K. Alfred Yung
Patrick Y. Wen
Andrew B. Lassman
Markus Joerger
Ghazaleh Tabatabai
Jordi Rodon
Ralph Tiedt
Sylvia Zhao
Tiina Kirsilae
Yi Cheng
Sergio Vicente
O. Alejandro Balbin
Hefei Zhang
Wolfgang Wick

Purpose To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutation or protein loss.

Keywords:

Tensin
C-Met
Phosphatase
Capmatinib
Mutation
Buparlisib
Glioblastoma
Cancer research
PTEN
Medicine
Gastroenterology
Nausea
Stable Disease
Neurology
Constipation
Internal medicine
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations